Pub. Rec./Experimental Treatments for Terminal Conditions and Life-threatening Rare Diseases
Summary
HB 1383 creates a public-records exemption for certain information contained in the Department of Health’s annual public report on experimental treatment outcomes and safety signals. The bill applies to the report required under s. 499.0295, Florida Statutes, which governs experimental treatments for terminal conditions and life-threatening rare diseases under the Promising Pathways Act. Under the bill, the health information and proprietary pricing information included in that report would be confidential and exempt from Florida’s public records law and the related constitutional right of access.
The bill’s stated purpose is to protect highly sensitive patient information. It includes a legislative finding that disclosure of this information could harm patients by exposing personal health data and that individuals seeking experimental treatments have a strong expectation of privacy. The exemption is framed as applying to aggregate reporting, but only to the extent the report contains health information and proprietary pricing information that the Legislature deems sensitive.
Impact
HB 1383 would amend Florida Statutes section 499.0295 to narrow public access to certain information in the Department of Health’s annual experimental-treatment report. In practical terms, it would shield patient-related health data and proprietary pricing information from disclosure under Florida’s public records law and the state constitutional access provision. The bill also contains a contingent effective date, meaning it would take effect only if HB 1381 or similar legislation becomes law in the same session, since the two measures are linked.
Sentiment
There is no recorded committee transcript or vote history in the provided materials, so no direct debate or recorded support/opposition is available. Based on the bill text, the measure appears to be presented as a privacy-protection bill rather than a controversial policy change, with its justification centered on protecting vulnerable patients and sensitive medical information. The absence of recorded opposition or amendments in the provided context suggests the bill’s sentiment cannot be assessed beyond its stated protective purpose.
Contention
The main point of potential contention is the balance between transparency and privacy. Supporters would likely argue that patients with terminal conditions or rare diseases deserve strong confidentiality protections, especially where experimental treatments and pricing information are involved. Opponents, if any, could argue that exempting information from public disclosure reduces oversight of experimental-treatment outcomes, pricing practices, and the public’s ability to evaluate the program’s effectiveness. The bill specifically targets health information and proprietary pricing data, so the scope of the exemption and whether it is too broad would be the likely area of dispute.